Biomarker & Intervention Discovery
Irritable Bowel Syndrome (IBS)
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
Spontaneous remissionIBS is chronic and remitting; spontaneous 'remission' (symptom resolution without treatment) in ~30-40% at 2 years but…
Best-intervention remissionLow-FODMAP diet: 50-80% symptomatic response; gut-directed hypnotherapy: 70-80% response, durable at 5 years; CBT:…
Gap sizeLarge — effective interventions exist but access to diet counselling, hypnotherapy, and CBT is limited; overreliance…
Primary barrieraccess/practice
Full remission profile →
Remission & chronicity
Spontaneous remission
IBS is chronic and remitting; spontaneous 'remission' (symptom resolution without treatment) in ~30-40% at 2 years but symptom recurrence common; 10-20% develop persistent daily symptoms; <10% achieve permanent remission
Best-intervention remission
Low-FODMAP diet: 50-80% symptomatic response; gut-directed hypnotherapy: 70-80% response, durable at 5 years; CBT: 60-70% response; rifaximin for IBS-D: 40% vs 31% placebo (modest but significant); neuromodulators (amitriptyline, nortriptyline): 60-70% response in IBS-D/IBS-M
Gap size
Large — effective interventions exist but access to diet counselling, hypnotherapy, and CBT is limited; overreliance on antispasmodics and antidiarrheals
Primary barrier
access/practice
Gut-directed hypnotherapy has the strongest long-term evidence of any IBS treatment but virtually no trained therapists; FODMAP diet requires skilled dietitian; pharmacotherapy (linaclotide, plecanatide, eluxadoline) effective but expensive; most patients manage with OTC antispasmodics indefinitely
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Irritable Bowel Syndrome (IBS)” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."